Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

Kenemans, P.; Bundred, Nigel; Foidart, Jean Michel; Kubista, E.; Schoultz, Bo von; Sismondi, P; Vassilopoulou‐Sellin, Rena; Yip, Cheng Har; Egberts, Jan F M; Mol-Arts, Mirjam; Mulder, Roel; Os, Steve van; Beckmann, Matthias W.

doi:10.1016/s1470-2045(08)70341-3

Cited by 287 publications

(147 citation statements)

References 33 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Tibolone (1.25 and 2.5 mg, respectively) increased lumbar and hip bone mineral density to a significantly greater extent than placebo in women with and without osteoporosis (Kenemans et al, 2009), as it was shown with a dose of 1.25 mg/day compared with raloxifene in a study of older osteopenic women (mean age 66 years) . The lower dose also reduced the risk of vertebral and non-vertebral fractures in older osteoporotic women (mean age 68.3 years) in the LIFT study (Cummings et al, 2008).…”

Section: Tibolone and Prevention Of Fracturesmentioning

confidence: 69%

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

Lamarca¹

2012

Osteoporosis

View full text Add to dashboard Cite

Section: Tibolone and Prevention Of Fracturesmentioning

confidence: 69%

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

Lamarca¹

2012

Osteoporosis

View full text Add to dashboard Cite

“…None of the three studies showed an increase in death from the disease. [42][43][44] Data derived from observational studies, including two large metaanalyses, do not show an increase in recurrences or death rate in breast cancer survivors using HT.…”

Section: Breast Cancer Survivorsmentioning

confidence: 99%

South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014

Guidozzi

Alperstein²,

Bagratee

et al. 2014

S Afr Med J

View full text Add to dashboard Cite

The South African Menopause Society (SAMS) consensus position statement on menopausal hormone therapy (HT) 2014 is a revision of the SAMS Council consensus statement on menopausal HT published in the SAMJ in May 2007. Information presented in the previous statement has been re-evaluated and new evidence has been incorporated. While the recommendations pertaining to HT remain similar to those in the previous statement, the 2014 revision includes a wider range of clinical benefits for HT, the inclusion of non-hormonal alternatives such as selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors for the management of vasomotor symptoms, and an appraisal of bioidentical hormones and complementary medicines used for treatment of menopausal symptoms. New preparations that are likely to be more commonly used in the future are also mentioned. The revised statement emphasises that commencing HT during the 'therapeutic window of opportunity' maximises the benefit-to-risk profile of therapy in symptomatic menopausal women.

show abstract

“…However, the study lacked the power to assess tibolone alone (without aromatase inhibitors) on risk of breast cancer recurrence. 5 Other hormonal preparations such as progestins and androgens may play a role in managing menopausal symptoms, but require further investigation. 6 …”

Section: Hormone Replacement Therapy In Breast Cancer Survivorsmentioning

confidence: 99%

Menopausal symptoms in breast cancer survivors: management update

Cusack

Brennan²,

Baber³

et al. 2013

Br J Gen Pract

View full text Add to dashboard Cite

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

Cited by 287 publications

References 33 publications

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014

Menopausal symptoms in breast cancer survivors: management update

Contact Info

Product

Resources

About